Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline

PUBLIC · NUVBApr 10, 2024•over 2 years ago

Acquiring Company

Nuvation Bio

Acquired Company

AnHeart Therapeutics

New YorkNew YorkBiotechnologyHealthcareHealth CareTherapeuticsBiopharmaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Nuvation Bio Inc., a late-stage global biopharmaceutical company, has successfully completed the acquisition of AnHeart Therapeutics Ltd. This acquisition transforms Nuvation Bio into a well-capitalized, late-stage, global oncology company, expanding its pipeline and positioning it to become a commercial organization.

Company Information

Company

Nuvation Bio

Location

New York, New York, United States

About

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.

Don't miss Nuvation Bio's next move

Get an email the moment Nuvation Bio makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Colleen
Likely contact at this company
••••••••@••••••••

See Colleen's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Nuvation Bio's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired AnHeart Therapeutics?

AnHeart Therapeutics was acquired by Nuvation Bio, based in New York. The deal was reported on April 10, 2024. Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio is publicly traded (NUVB) and operates in Biotechnology.

When did Nuvation Bio acquire AnHeart Therapeutics?

Nuvation Bio's acquisition of AnHeart Therapeutics was reported on April 10, 2024. Nuvation Bio Inc., a late-stage global biopharmaceutical company, has successfully completed the acquisition of AnHeart Therapeutics Ltd. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does AnHeart Therapeutics do?

AnHeart Therapeutics Ltd. is a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. It is privately held, operating in Biotechnology, and is based in New York.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.